Drug-Device Combination Products Market by Product (Drug-eluting Stent, Infusion Pump, Photodynamic Therapy, Antimicrobial Wound Dressing, Prefilled Syringe, Drug-eluting Balloon, Nebulizer, Inhaler, Transdermal Delivery System, and Others), Application (Cardiovascular Treatment, Diabetes, Respiratory Problem, Cancer Treatment, Antimicrobial Application, and Others), and End User (Hospital & Clinic, Ambulatory Surgical Center, Home Care Setting, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025 Update Available On-Demand
|
LI_18667
|
Pages: 244
|
Sep
2018 |
5640 Views
|
|
|
|
Author(s) :
Mayuri Srivastava & Pallavi Jaiswal
|
Tables: 77
|
Charts: 78
|
Formats*:
|
|
Drug-Device Combination Products Market Overview:
The global drug-device combination products market was valued at $81,374 million in 2017 and is projected to reach $139,193 million by 2025 at a CAGR of 6.9% from 2018 to 2025.
Drug-device combination products are medical devices, which consist of a device and active pharmaceutical ingredients that are physically or chemically combined together as a “single-entity”. These products lead to safer, effective management, and treatment of several disorders, owing to precise drug delivery, local administration, and individualized treatment. Major drug-device combination products include drug-eluting stents, infusion pumps, inhalers, transdermal delivery systems, prefilled syringes, and others. These technologically advanced products are used to manage and treat a number of chronic disorders such as cancer, diabetes, respiratory issues, cardiovascular disorders, wound healing, and others.
Get more information on this report : Request Sample Pages
Market Dynamics
The growth of the Global Drug-device Combination Products Market is driven by rise in incidence of chronic diseases such as diabetes, cancer, and respiratory problems, increase in casualties owing to accidents and trauma, rise in geriatric population, growth in home-based healthcare market, and technological advancements such as development of prefilled syringes. However, factors, such as unnoticed complications of drug-device combination products, number of product recalls, and stringent government regulations, hamper the market growth. Conversely, rise in healthcare infrastructure and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.
Market Segmentation
The global drug-device combination products market is segmented based on product, application, end user, and region. On the basis of product, the market is segmented into drug-eluting stent, infusion pump, photodynamic therapy, antimicrobial wound dressing, prefilled syringe, drug-eluting balloon, nebulizer, inhaler, transdermal delivery system, and others.
Drug-eluting stents are further sub-segmented into coronary stents and peripheral vascular stents. The infusion pumps segment is further divided into implantable infusion pump, insulin infusion pump, patient-controlled analgesia pump, and ambulatory infusion pump. Similarly, prefilled syringes are further categorized into single-chamber prefilled syringes, dual-chamber prefilled syringes, and customized prefilled syringes. The drug-eluting balloon segment is bifurcated into coronary drug-eluting balloon and peripheral drug-eluting balloon. The inhaler segment is further segmented into drug powder inhaler (DPI), metered dose inhaler (MDI), and soft mist inhaler (SMI). Lastly, the transdermal delivery system segment is bifurcated into passive delivery system and active delivery system.
The transdermal delivery system segment accounted for the largest market share in 2017 and is expected to continue this trend throughout the forecast period. On the other hand, the prefilled syringe segment is anticipated to grow at a significant CAGR of 9.9% during the forecast period.
Get more information on this report : Request Sample Pages
On the basis of application, the market is categorized into cardiovascular treatment, diabetes, respiratory problem, cancer treatment, antimicrobial application, and other applications. The respiratory problem segment accounted for the largest market share in 2017, whereas the antimicrobial application segment is expected to register the highest growth rate during the forecast period.
Get more information on this report : Request Sample Pages
Depending on end user, the market is fragmented into hospital & clinic, ambulatory surgery center (ASC), home care setting, and other end users. The hospital & clinic segment held the largest share of the market in 2017, whereas the ambulatory surgical center segment is expected to register the highest growth rate during the forecast period.
Get more information on this report : Request Sample Pages
Based on region, the global market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2017, followed by Europe. On the other hand, the Asia-Pacific is anticipated to dominate the market during the forecast period, owing to large population base, increase in disposable income, and improvement in patient awareness about combination devices. Moreover, Asia is a large continent, and is a home to some of the world’s highly populous countries. This region has emerged as an epicenter of numerous chronic disordes.
Get more information on this report : Request Sample Pages
The key players of this market include Abbott Laboratories, Medtronic plc, Smith & Nephew plc, Boston Scientific Corporation, GlaxoSmithKline plc, Becton, Dickinson and Company, Johnson & Johnson, Novartis AG, Bayer AG, and Baxter International, Inc.
The other players in the value chain include B. Braun Melsungen AG, Cook Medical, ICU Medical, Inc., Moog, Inc., and C.R. Bard, Inc. These players are not profiled in the report and the same can be included on request.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global drug-device combination products market with the current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
- A comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global & regional scales are provided.
- The key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Drug-Device Combination Products Market Key Segments:
By Product
- Drug-eluting stent
- Coronary drug-eluting stent
- Peripheral drug-eluting stent
- Infusion pump
- Implantable infusion pump
- Insulin infusion pump
- Patient-controlled analgesia pump
- Ambulatory infusion pump
- Photodynamic therapy
- Antimicrobial wound dressing
- Prefilled syringe
- Single-chamber prefilled syringe
- Dual-chamber prefilled syringe
- Customized prefilled syringe
- Drug-eluting balloon
- Coronary drug-eluting balloon
- Peripheral drug-eluting balloon
- Nebulizer
- Inhaler
- Drug powder inhaler (DPI)
- Metered dose inhaler (MDI)
- Soft mist inhaler (SMI)
- Transdermal delivery system
- Passive delivery system
- Active delivery system
- Other drug device combination products
By Wound Type
- Cardiovascular disease
- Diabetes
- Respiratory problem
- Cancer treatment
- Antimicrobial application
- Other applications
By End User
- Hospital & clinic
- Ambulatory surgery center (ASC)
- Home care setting
- Other end users
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of key players profiled in the report
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key findings
3.2.1. Top Winning Strategies
3.2.2. Top Investment Pockets
3.3. Top Player Positioning, 2017
3.4. Government Regulations
3.4.1. U.S. FDA
3.4.2. Europe CE Mark
3.4.3. Ministry of Health, Labor, and Welfare (MHLW)
3.4.4. Central Drug Standards Control Organization (CDSCO)
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Rapidly aging population and favorable demographics worldwide
3.5.1.2. Rise in incidence of chronic conditions
3.5.1.3. Technological advancements in drug-device combination products
3.5.1.4. Growth in home-based healthcare market
3.5.2. Restraints
3.5.2.1. Stringent approval process of these products
3.5.2.2. Occurrence of several errors and number of product recalls
3.5.3. Opportunities
3.5.3.1. Opportunities in emerging markets
3.5.4. Impact Analyses
3.6. Patent Analysis (2013-2018)
3.6.1. Patent analysis, by year
3.6.2. Patent analysis, by country
CHAPTER 4: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Drug-Eluting Stents
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Coronary Drug-Eluting Stents
4.2.2.1.1. Market size and forecast
4.2.2.2. Peripheral Drug-Eluting Stents
4.2.2.2.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.3. Infusion Pumps
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Implantable Infusion Pumps
4.3.2.1.1. Market size and forecast
4.3.2.2. Insulin Infusion Pumps
4.3.2.2.1. Market size and forecast
4.3.2.3. Patient-controlled Analgesia Pumps
4.3.2.3.1. Market size and forecast
4.3.2.4. Ambulatory Infusion Pumps
4.3.2.4.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.4. Photodynamic Therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Antimicrobial Wound Dressings
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.6. Prefilled Syringes
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by type
4.6.2.1. Single-Chamber Prefilled Syringes
4.6.2.1.1. Market size and forecast
4.6.2.2. Dual-Chamber Prefilled Syringes
4.6.2.2.1. Market size and forecast
4.6.2.3. Customized Prefilled Syringes
4.6.2.3.1. Market size and forecast
4.6.3. Market size and forecast, by region
4.7. Drug-Eluting Balloons
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by type
4.7.2.1. Coronary Drug-Eluting Balloons
4.7.2.1.1. Market size and forecast
4.7.2.2. Peripheral Drug-Eluting Balloons
4.7.2.2.1. Market size and forecast
4.7.3. Market size and forecast, by region
4.8. Nebulizers
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.9. Inhalers
4.9.1. Key market trends, growth factors, and opportunities
4.9.2. Market size and forecast, by type
4.9.2.1. Drug powdered inhalers (DPIs)
4.9.2.1.1. Market size and forecast
4.9.2.2. Metered dose inhalers (MDIs)
4.9.2.2.1. Market size and forecast
4.9.2.3. Soft mist inhalers (SMIs)
4.9.2.3.1. Market size and forecast
4.9.3. Market size and forecast, by region
4.10. Transdermal Delivery Systems
4.10.1. Key market trends, growth factors, and opportunities
4.10.2. Market size and forecast, by type
4.10.2.1. Active Transdermal Systems
4.10.2.1.1. Market size and forecast
4.10.2.2. Passive Transdermal Systems
4.10.2.2.1. Market size and forecast
4.10.3. Market size and forecast, by region
4.11. Other products
4.11.1. Key market trends, growth factors, and opportunities
4.11.2. Market size and forecast, by region
CHAPTER 5: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cardiovascular Disorders
5.2.1. Market size and forecast, by type
5.3. Diabetes
5.3.1. Market size and forecast, by region
5.4. Respiratory Problems
5.4.1. Market size and forecast, by region
5.5. Cancer Treatment
5.5.1. Market size and forecast, by region
5.6. Antimicrobial Application
5.6.1. Market size and forecast, by region
5.7. Other Applications
5.7.1. Market size and forecast, by region
CHAPTER 6: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals & Clinics
6.2.1. Market size and forecast, by region
6.3. Ambulatory Surgery Centers (ASCs)
6.3.1. Market size and forecast, by region
6.4. Home Care Settings
6.4.1. Market size and forecast, by region
6.5. Other End Users
6.5.1. Market size and forecast, by region
CHAPTER 7: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America drug-device combination products market, by country
7.2.2.1. U.S.
7.2.2.2. Canada
7.2.2.3. Mexico
7.2.3. North America market size and forecast, by product
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe market size and forecast, by country
7.3.2.1. Germany
7.3.2.2. France
7.3.2.3. UK
7.3.2.4. Italy
7.3.2.5. Spain
7.3.3. Rest of Europe
7.3.4. Europe market size and forecast, by product
7.3.5. Europe market size and forecast, by application
7.3.6. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific market size and forecast, by country
7.4.2.1. Japan
7.4.2.2. China
7.4.2.3. India
7.4.2.4. Australia
7.4.2.5. South Korea
7.4.2.6. Rest of Asia-Pacific
7.4.3. Asia-Pacific market size and forecast, by product
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by country
7.5.2.1. Brazil
7.5.2.2. Saudi Arabia
7.5.2.3. South Africa
7.5.2.4. Rest of LAMEA
7.5.3. LAMEA market size and forecast, by product
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating product segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Bayer AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating product segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Baxter International Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Becton, Dickinson and Company
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Boston Scientific Corporation
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product Portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Johnson & Johnson
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Medtronic plc
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. GlaxoSmithKline plc
8.8.1. Company Overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Novartis International AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Smith & Nephew plc
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. MEDICAL DEVICE CLASSIFICATION IN THE U.S.
TABLE 02. GLOBAL DRUGS-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 03. GLOBAL DRUG-ELUTING STENTS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 04. DRUG-ELUTING STENTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. GLOBAL INFUSION PUMPS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 06. INFUSION PUMPS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 07. PHOTODYNAMIC THERAPY SYSTEMS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 08. ANTIMICROBIAL WOUND DRESSINGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 09. GLOBAL PREFILLED SYRINGES MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 10. PREFILLED SYRINGES MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 11. GLOBAL DRUG-DEVICE COMBINATION INFUSION PUMPS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 12. DRUG-ELUTING BALLOONS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 13. NEBULIZERS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 14. GLOBAL INHALERS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 15. INHALERS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 16. GLOBAL TRANSDERMAL DELIVERY SYSTEMS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 17. TRANSDERMAL DELIVERY SYSTEMS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 18. OTHERS DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 19. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 20. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2017-2025 ($MILLION)
TABLE 21. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR DIABETES, BY REGION, 2017-2025 ($MILLION)
TABLE 22. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR RESPIRATORY PROBLEMS, BY REGION, 2017-2025 ($MILLION)
TABLE 23. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR CANCER TREATMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 24. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR ANTIMICROBIAL APPLICATION, BY REGION, 2017-2025 ($MILLION)
TABLE 25. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR ANTIMICROBIAL APPLICATION, BY REGION, 2017-2025 ($MILLION)
TABLE 26. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 27. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2017-2025 ($MILLION)
TABLE 28. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR AMBULATORY SURGERY CENTERS (ASCS), BY REGION, 2017-2025 ($MILLION)
TABLE 29. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR HOME CARE SETTINGS, BY REGION, 2017-2025 ($MILLION)
TABLE 30. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2017-2025 ($MILLION)
TABLE 31. DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 32. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 33. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 34. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 35. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 36. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 37. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 38. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 39. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 40. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 41. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 42. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 43. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 44. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 45. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 46. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 47. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 48. ABBOTT: COMPANY SNAPSHOT
TABLE 49. ABBOTT: OPERATING SEGMENTS
TABLE 50. ABBOTT: PRODUCT PORTFOLIO
TABLE 51. BAYER: COMPANY SNAPSHOT
TABLE 52. BAYER: OPERATING PRODUCT SEGMENTS
TABLE 53. BAYER: PRODUCT PORTFOLIO
TABLE 54. BAXTER: COMPANY SNAPSHOT
TABLE 55. BAXTER: OPERATING SEGMENTS
TABLE 56. BAXTER: PRODUCT PORTFOLIO
TABLE 57. BD: COMPANY SNAPSHOT
TABLE 58. BD: FRANCHISES
TABLE 59. BD: PRODUCT PORTFOLIO
TABLE 60. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 61. BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 62. BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 63. J&J: COMPANY SNAPSHOT
TABLE 64. J&J: OPERATING SEGMENTS
TABLE 65. J&J: PRODUCT PORTFOLIO
TABLE 66. MEDTRONIC: COMPANY SNAPSHOT
TABLE 67. MEDTRONIC: OPERATING SEGMENTS
TABLE 68. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 69. GSK: COMPANY SNAPSHOT
TABLE 70. GSK: OPERATING SEGMENTS
TABLE 71. GSK: PRODUCT PORTFOLIO
TABLE 72. NOVARTIS: COMPANY SNAPSHOT
TABLE 73. NOVARTIS: OPERATING SEGMENTS
TABLE 74. NOVARTIS: PRODUCT PORTFOLIO
TABLE 75. SMITH & NEPHEW: COMPANY SNAPSHOT
TABLE 76. SMITH & NEPHEW: PRODUCT SEGMENTS
TABLE 77. SMITH & NEPHEW: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. DRUG-DEVICE COMBINATION MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES (2015-2018)
FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2015-2018)
FIGURE 04. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 05. TOP INVESTMENT POCKETS
FIGURE 06. TOP PLAYER POSITIONING, 2017
FIGURE 07. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 08. IMPACT ANALYSES
FIGURE 09. PATENTS REGISTERED/APPROVED IN THE WORLD, BY TYPE OF PRODUCT, 2013-2018
FIGURE 10. PATENTS ANALYSIS BY YEAR, 2013 THROUGH 2018
FIGURE 11. PATENT ANALYSIS, BY COUNTRY, 2013-2018
FIGURE 12. GLOBAL CORONARY DRUG-ELUTING STENTS MARKET, 2017-2025 ($MILLION)
FIGURE 13. GLOBAL PERIPHERAL DRUG-ELUTING STENTS MARKET, 2017-2025 ($MILLION)
FIGURE 14. GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, 2017-2025 ($MILLION)
FIGURE 15. GLOBAL INSULIN INFUSION PUMPS MARKET, 2017-2025 ($MILLION)
FIGURE 16. GLOBAL PATIENT-CONTROLLED ANALGESIA PUMPS MARKET, 2017-2025 ($MILLION)
FIGURE 17. GLOBAL AMBULATORY INFUSION PUMPS MARKET, 2017-2025 ($MILLION)
FIGURE 18. GLOBAL SINGLE-CHAMBER PREFILLED SYRINGES MARKET, 2017-2025 ($MILLION)
FIGURE 19. GLOBAL DUAL-CHAMBER PREFILLED SYRINGES MARKET, 2017-2025 ($MILLION)
FIGURE 20. GLOBAL CUSTOMIZED PREFILLED SYRINGES MARKET, 2017-2025 ($MILLION)
FIGURE 21. GLOBAL CORONARY DRUG-ELUTING BALLOONS MARKET, 2017-2025 ($MILLION)
FIGURE 22. GLOBAL PERIPHERAL DRUG-ELUTING BALLOONS MARKET, 2017-2025 ($MILLION)
FIGURE 23. GLOBAL DRY POWDER INHALERS MARKET, 2017-2025 ($MILLION)
FIGURE 24. GLOBAL METERED DOSE INHALERS MARKET, 2017-2025 ($MILLION)
FIGURE 25. GLOBAL SOFT MIST INHALERS MARKET, 2017-2025 ($MILLION)
FIGURE 26. GLOBAL ACTIVE TRANSDERMAL SYSTEMS MARKET, 2017-2025 ($MILLION)
FIGURE 27. GLOBAL PASSIVE TRANSDERMAL SYSTEMS MARKET, 2017-2025 ($MILLION)
FIGURE 28. ESTIMATED NUMBER OF DIAGNOSED AND UNDIAGNOSED DIABETES AMONG ADULTS AGED 18 YEARS, U.S., 2015
FIGURE 29. U.S. DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 30. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 31. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 32. LUNG CANCER INCIDENCE IN THE EUROPEAN REGION, BY GENDER, 2012 (PER 100,000 POPULATION)
FIGURE 33. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 34. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 35. UK DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 36. ITALY DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 37. SPAIN DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 38. REST OF EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 39. JAPAN DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 40. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 41. INDIA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 42. AUSTRALIA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 43. SOUTH KOREA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 44. REST OF ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 45. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 46. SAUDI ARABIA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 47. SOUTH AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 48. REST OF LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
FIGURE 49. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 50. ABBOTT: REVENUE SHARE, BY SEGMENT, 2017 (%)
FIGURE 51. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 52. BAYER: NET SALES, 2015-2017 ($MILLION)
FIGURE 53. BAYER: REVENUE SHARE, BY SEGMENT, 2017 (%)
FIGURE 54. BAYER: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 55. BAXTER: NET SALES, 2015-2017 ($MILLION)
FIGURE 56. BAXTER: REVENUE SHARE, BY SEGMENT, 2017 (%)
FIGURE 57. BAXTER: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 58. BD: NET SALES, 2015-2017 ($MILLION)
FIGURE 59. BD: REVENUE SHARE, BY SEGMENT, 2017 (%)
FIGURE 60. BD: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 61. BOSTON SCIENTIFIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 62. BOSTON SCIENTIFIC: NET SALES, BY SEGMENT, 2017 (%)
FIGURE 63. BOSTON SCIENTIFIC: NET SALES, BY GEOGRAPHY, 2017 (%)
FIGURE 64. J&J: NET SALES, 2015-2017 ($MILLION)
FIGURE 65. J&J: REVENUE SHARE, BY SEGMENT, 2017 (%)
FIGURE 66. J&J: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 67. MEDTRONIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 68. MEDTRONIC: NET SALES, BY SEGMENT, 2017 (%)
FIGURE 69. MEDTRONIC: NET SALES, BY GEOGRAPHY, 2017 (%)
FIGURE 70. GSK: NET SALES, 2015-2017 ($MILLION)
FIGURE 71. GSK: REVENUE SHARE, BY SEGMENT, 2017 (%)
FIGURE 72. GSK: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 73. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 74. NOVARTIS: REVENUE SHARE, BY PRODUCT, 2017 (%)
FIGURE 75. NOVARTIS: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 76. SMITH & NEPHEW: NET SALES, 2015-2017 ($MILLION)
FIGURE 77. SMITH & NEPHEW: REVENUE SHARE, BY PRODUCT, 2017 (%)
FIGURE 78. SMITH & NEPHEW: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
Utilization of drug-device combination products is expected to witness a significant rise with increase in prevalence of chronic diseases, such as diabetes and cancer, and growth in awareness about the development of technologically advanced combination products. Increase in usage of drug-device combination products for the treatment of cancer and respiratory problems by physicians in the developed regions have fueled the interest of the healthcare industry.
Increase in number of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma as well as rise in awareness about the availability of economical combination devices are expected to drive the growth of the drug-device combination products market. However, stringent governmental regulations and post-operative complications related to combination products hamper the market growth. According to the CXOs, there is an increase in the adoption of prefilled syringes that help treat chronic disorders.
This increase is majorly due to rise in prevalence of chronic diseases, surge in geriatric population who are more prone to chronic disorders, and improvement in reimbursement scenario.
The use of drug-device combination products is expected to increase in future. CXOs state that the use of these devices is the highest in North America, owing to higher government expenditure on healthcare and better reimbursement policies, followed by Europe and Asia-Pacific.
Download Sample
Purchase Full Report of
Drug-Device Combination Products Market- Global Opportunity Analysis and Industry Forecast, 2017-2025
- Online Only
- $3,456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3,840
- Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5,370
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6,450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8,995
- Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"Drug-Device Combination Products Market"
Purchase Enquiry